Hirudo (Leech) for proliferative vitreous retinopathy: A protocol for systemic review and meta-analysis
Huang H, Lei R, Li Y, Huang Q, Gao N, Zou W (2021) · Medicine (Baltimore) · n=0
Perfil del estudio
- Diseño
- pre-registered systematic review and meta-analysis protocol for Hirudo (leech) or Hirudo-containing Chinese compound prescriptions in proliferative vitreous retinopathy (Chengdu University of Traditional Chinese Medicine, China)
- Tamaño de la muestra (n)
- —
- Intervención
- Planned synthesis of randomized controlled trials in English or Chinese on Hirudo (leech) and Hirudo-containing compound prescriptions for proliferative vitreous retinopathy (PVR)
- Comparador
- Cross-trial: conventional ophthalmologic care without Hirudo product
- Punto final primario
- Change in vitreous opacity, vision changes, anterior macular membrane formation, retinal detachment recurrence, and adverse-event incidence
- Resultado primario
- Pre-registered protocol only - no results yet available; protocol registered at OSF (10.17605/OSF.IO/FP7VG); planned 8-database search including Cochrane, PubMed, MEDLINE, EMBASE, CNKI, CBM, VIP, and Wanfang
- Duración del seguimiento
- to be determined per included studies
- PMID
- 33546086
Hallazgos clave
- First pre-registered systematic review protocol for Hirudo/leech-containing therapeutics in proliferative vitreous retinopathy
- Plans to incorporate Chinese-language databases (CNKI, CBM, VIP, Wanfang) often missing from Western reviews
- Includes both whole-leech therapy and Hirudo-containing Chinese herbal compound prescriptions in scope
- Documents the emerging investigation of leech-derived therapeutics in ophthalmologic indications outside the FDA K040187 clearance
- Pre-registration at OSF supports methodological transparency
Limitaciones
- Protocol only - no results available at time of registry inclusion
- Scope conflates whole-leech therapy with multi-ingredient Chinese herbal compound prescriptions - mechanistic specificity reduced
- Chinese-language source heterogeneity may produce quality challenges
- PVR is a niche ophthalmologic indication - generalizability to broader leech-therapy literature limited
- Investigators are from a single Chinese TCM institution - external validation pending
Implicaciones clínicas
Huang 2021 is a pre-registered systematic review protocol on Hirudo (leech) therapeutics for proliferative vitreous retinopathy. The trial is included in this registry to document the emerging Chinese investigation of leech-derived ophthalmologic indications - a use case largely absent from the Western FDA-cleared K040187 framework. The protocol's ultimate publication will be informative for understanding the global leech-therapy evidence base. ASH editorial team should track the eventual full-publication output of this systematic review.
Estudios relacionados
The Effectiveness of Leech Therapy in Chronic Low Back Pain
Hohmann CD, Stange R, Steckhan N, Robens S, Ostermann T, Paetow A, Michalsen A (2018)
Hirudotherapy for limb ischemia in the pediatric intensive care unit: a retrospective observational cohort
Resch JC, Hedstrom R, Steiner ME, Said SM, Somani A (2023)
Study of the effect of leeching on plasma endothelin and soluble interleukin-2 receptor in patients with systemic lupus erythematosus
Cheng SP, Liu JL, Yuan J (2005)
Medicinal leech therapy in pain syndromes: a narrative review
Koeppen D, Aurich M, Rampp T (2013)